Alzheimer's Drug Donanemab Slows Cognitive and Functional Decline in Phase 3 Study

Findings from a Phase 3 study show donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer's disease. Donanemab met the primary endpoint of change, which measured measures cognition and activities of daily living such as managing finances, driving, engaging in hobbies, and conversing about current events, from baseline until 18 months on the integrated Alzheimer's Disease Rating Scale (iADRS). All secondary endpoints of cognitive and functional ...